{
    "info": {
        "nct_id": "NCT00984282",
        "official_title": "A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",
        "inclusion_criteria": "* Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell)\n* Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are eligible provided that the histology has no medullary differentiation nor anaplastic features\n* Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors] should be used as a basis for the assessment of disease progression)\n* RAI (radioactive iodine) refractory\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma)\n* Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF (vascular endothelial growth factor) or VEGF Receptors or other targeted agents\n* Prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose chemotherapy for radiosensitization is allowed) or Thalidomide or any of its derivatives",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell)",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced or metastatic differentiated thyroid cancer",
                    "criterion": "differentiated thyroid cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "papillary",
                    "criterion": "thyroid cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "papillary"
                        }
                    ]
                },
                {
                    "exact_snippets": "follicular",
                    "criterion": "thyroid cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "follicular"
                        }
                    ]
                },
                {
                    "exact_snippets": "Hurthle cell",
                    "criterion": "thyroid cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "Hurthle cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are eligible provided that the histology has no medullary differentiation nor anaplastic features",
            "criterions": [
                {
                    "exact_snippets": "Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.)",
                    "criterion": "thyroid variant",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "poorly differentiated",
                                "insular",
                                "tall cell"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histology has no medullary differentiation",
                    "criterion": "medullary differentiation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "histology has no ... anaplastic features",
                    "criterion": "anaplastic features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors] should be used as a basis for the assessment of disease progression)",
            "criterions": [
                {
                    "exact_snippets": "Progression within 14 months",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* RAI (radioactive iodine) refractory",
            "criterions": [
                {
                    "exact_snippets": "RAI (radioactive iodine) refractory",
                    "criterion": "RAI (radioactive iodine)",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma)",
            "criterions": [
                {
                    "exact_snippets": "Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma)",
                    "criterion": "histologic subtypes of thyroid cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "anaplastic carcinoma",
                                "medullary carcinoma",
                                "lymphoma",
                                "sarcoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF (vascular endothelial growth factor) or VEGF Receptors or other targeted agents",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-cancer treatment with tyrosine kinase inhibitors",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "tyrosine kinase inhibitors"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior anti-cancer treatment with ... monoclonal antibodies (licensed or investigational) that target VEGF (vascular endothelial growth factor) or VEGF Receptors",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "monoclonal antibodies"
                        },
                        {
                            "requirement_type": "target",
                            "expected_value": [
                                "VEGF",
                                "VEGF Receptors"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior anti-cancer treatment with ... other targeted agents",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "other targeted agents"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose chemotherapy for radiosensitization is allowed) or Thalidomide or any of its derivatives",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-cancer treatment for thyroid cancer with use of chemotherapy",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "cancer type",
                            "expected_value": "thyroid cancer"
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "chemotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior anti-cancer treatment for thyroid cancer with use of ... Thalidomide or any of its derivatives",
                    "criterion": "prior anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "cancer type",
                            "expected_value": "thyroid cancer"
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "Thalidomide",
                                "Thalidomide derivatives"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}